Galectin Therapeutics (GALT) Common Equity (2010 - 2026)

Galectin Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at -$132.0 million for Q1 2026.

• On a quarterly basis, Common Equity fell 15.77% year-over-year to -$132.0 million in Q1 2026; TTM through Mar 2026 was -$132.0 million, a 15.77% decrease from a year earlier, with the FY2025 full-year figure at -$127.9 million, down 22.07% from the prior year.
• Common Equity slipped to -$132.0 million in Q1 2026 per GALT's latest filing, from -$127.9 million in the prior quarter.
• Across five years, Common Equity topped out at -$7.9 million in Q1 2022 and bottomed at -$132.0 million in Q1 2026.
• The 5-year median for Common Equity is -$62.0 million (2023), against an average of -$72.9 million.
• Across the five-year window, Common Equity tumbled 3898.1% in 2022 and changed 0.0% in 2024, its largest moves.
• Year by year, Common Equity stood at -$33.9 million in 2022, then sank by 82.69% to -$62.0 million in 2023, then plunged by 69.12% to -$104.8 million in 2024, then slipped by 22.07% to -$127.9 million in 2025, then dropped by 3.16% to -$132.0 million in 2026.
• Per Business Quant, the three latest GALT Common Equity figures stand at -$132.0 million (Q1 2026), -$127.9 million (Q4 2025), and -$125.3 million (Q3 2025).